Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
Here we report a case of Pyoderma gangrenosum (PG) associated with Crohn's disease successfully treated with infliximab. The efficacy of this drug in many inflammatory diseases has already been reported, but its use in PG has only been seen in very few cases. Our study confirms that this therapy is a valid alternative solution for treating PG, which is often unresponsive to conventional therapies.
Zaccagna
Alessandro
A
Institute for Cancer Research and Treatment (IRCC), Operative Unit of Dermatologic Surgery, Str.Prov.142, Km 3.95, 10060 Candiolo, Italy.
Bertone
Alberto
A
Puiatti
Paolo
P
Picciotto
Franco
F
Sprujevnik
Tatiana
T
Santucci
Renato
R
Rossini
Francesco Paolo
FP
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D003424:Crohn Disease / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D003937:Diagnosis, Differential; D016523:Foot Ulcer / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D017511:Pyoderma Gangrenosum / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab